drug · small molecule
tavapadon
pre_registrationupdated 6mo agoby $ABBV AbbVie Inc.🔗 ChEMBL
community read0 votes
Small molecule drug with a maximum clinical stage of Phase 3 (across all indications), with 3 investigational indications.
indications
indications
Parkinson's Disease
targets
D(1A) dopamine receptorD(1B) dopamine receptor
all catalysts(0)
nothing on the calendar yet
Trials studying tavapadon
- —Expanded Access to Tavapadon
- phase3Open-label Trial in Parkinson's Disease (PD)
- phase3Flexible-Dose Trial in Early Parkinson's Disease (PD)
- phase3Fixed-Dose Trial in Early Parkinson's Disease (PD)
- phase1A Study to Assess the Relative Bioavailability of Oral Tavapadon in Healthy Adult Participants
- phase3Flexible-Dose, Adjunctive Therapy Trial in Adults With Parkinson's Disease With Motor Fluctuations (TEMPO-3)
- phase1To Evaluate Pharmacokinetics (PK) and Safety of Tavapadon in Participants With Severe Renal Impairment Compared to Participants With Normal Renal Function
- phase1Multiple-dose Trial to Determine the Clinical Bioequivalence Between Tavapadon Tablets in Participants With Parkinson's Disease
News(8)
- Neurosterix nabs $105M, recruits Karuna veterans for schizophrenia pushAddex Therapeutics spinout Neurosterix will use the series B funds to advance an oral drug targeting M4, a muscarinic receptor also targeted by BMS’ Cobenfy, which introduced a new mechanism for tr…biospace · 4d ago
- With an approval apiece, the verdict is still out on AbbVie’s and BMS’ twin neuro buysAfter emraclidine’s schizophrenia fail and Cobenfy’s laggard launch, it’s too early to know who made the better buy: AbbVie, in its $8.7 billion Cerevel takeover in late 2023, or Bristol Myers Squi…biospace · 8d ago
- Cerevance Parkinson’s drug shortens 'off time' in Ph. 3, paving path to FDAThe Takeda spinout showed that a high dose of solengepras can shorten the periods during which difficult Parkinson’s disease symptoms like involuntary movements and sleepiness.biospace · 1mo ago
- Cerevance rescues its Parkinson's drug with phase 3 winCerevance's oral non-dopaminergic therapy has redeemed itself by improving both motor and non-motor symptoms in a phase 3 Parkinson's disease study.fiercebiotech · 1mo ago
- PhRMA names next CEO; Pierre Fabre takes third swing at Ebvallo approvalA former congressman will take over for prominent lobbyist Steve Ubl. Elsewhere, recent buyout deals paid dividends for Mirum and AbbVie.biopharma_dive · 1mo ago
- AbbVie wins FDA approval for Parkinson’s drug from $8.7B Cerevel takeoverIn the Phase 3 TEMPO program, AbbVie’s Juvmo elicited significant improvements in motor symptoms and prolonged periods with good symptom control.biospace · 1mo ago
- AbbVie's next-gen dopamine therapy for Parkinson's gets FDA approvalThe FDA approved AbbVie’s tavapadon, a next-generation therapy for Parkinson’s disease that's expected to provide the symptom relief of its predecessors but with fewer side effects. The dopamine ag…endpoints · 1mo ago
- AbbVie shares pressured as Q2 I&I beat falls below investor expectationsAbbVie investors’ sky-high expectations led to a 4% share decline on Friday as the company reported more modest consensus beats than expected.biospace · 3mo ago
Data sources
last refreshed 5h ago
Found something off?
comments(0)
5-min edit window · permanent after that